Q--NGS services to support clinical research

This Request for Quotation (RFQ) by the National Institutes of Health (NIH) seeks Next Generation Sequencing (NGS) services to detect genetic mutations in patients with bone marrow failure syndromes. The solicitation, number 75N98026Q00369, is a competitive combined synopsis/solicitation for commercial items, set aside for small businesses under NAICS code 621511. The contractor will perform genomic sequencing on patient samples (blood, bone marrow, plasma, FFPE tissue) to identify somatic and germline mutations relevant to hematologic conditions, covering over 300 genes. Key requirements include a 10-day turnaround time, secure electronic reporting, and demonstrated experience in longitudinal clinical research. Proposals will be evaluated based on technical capability (most important), past performance, and price. Responses are due by May 29, 2026, at 9:00 AM EDT.

The National Institutes of Health (NIH) is seeking Next Generation Sequencing (NGS) services to detect genetic mutations in bone marrow failure patients. This competitive solicitation, number 75N98026Q00369, is set aside for small businesses under NAICS code 621511. The contractor will perform genomic sequencing on patient samples, covering over 300 genes associated with hematologic conditions, including UBA1, TERT, and GATA2. Key requirements include a turnaround time of 10 calendar days or less, the ability to process multiple specimen types, and secure electronic reporting of results. Proposals will be evaluated based on technical capability (most important), past performance, and price. Responses are due by May 29, 2026, at 9:00 AM EDT, and must be submitted electronically. The period of performance is from June 1, 2026, to May 31, 2027. The project aims to support patient diagnosis, treatment decisions, and ongoing clinical research protocols for aplastic anemia and related disorders.

The National Institutes of Health (NIH) has issued a Request for Quotation (RFQ) for Next Generation Sequencing (NGS) services to support clinical and research activities related to bone marrow failure syndromes. The solicitation, identified as 75N98026Q00369/0003, seeks proposals for approximately 144 samples to be processed during the period of performance from June 1, 2026, to May 31, 2027. Key requirements include the contractor's ability to propose sequencing panels covering clinically relevant genes, maintain current CLIA certification, perform automated extraction of both DNA and RNA, provide materials for specimen shipment, and ensure secure electronic reporting of results. Samples may be shipped in multiple batches, and reports must identify clinically relevant mutations and provide sequencing analysis for ongoing research. The contractor must also safeguard patient-sensitive information.

This Request for Quotation (RFQ) 75N98026Q00369/0002 from the National Institutes of Health seeks Next Generation Sequencing (NGS) services for clinical and research activities related to bone marrow failure syndromes. The period of performance is from June 1, 2026, to May 31, 2027. Key requirements include a 10-calendar-day turnaround time for the entire workflow (specimen receipt through final analysis and reporting), use of sequencing methodologies compatible with existing longitudinal research datasets, and current CLIA certification for the contractor. The government emphasizes the critical need for consistency and reproducibility of longitudinal sequencing data. This RFQ is not a small business set-aside.

The National Institutes of Health (NIH) is issuing a Request for Quotation (RFQ) (Solicitation Number 75N98026Q00369) for Next Generation Sequencing (NGS) services. These services will support clinical and research activities related to bone marrow failure syndromes, including aplastic anemia. The requirement is a competitive combined synopsis/solicitation, set aside for small business concerns under NAICS code 621511 (Medical Laboratories). The selected contractor will perform genomic sequencing on patient-derived samples to detect somatic and germline mutations, covering over 300 genes associated with hematologic conditions. Key requirements include a turnaround time of 10 calendar days or less, secure electronic results, and standardized methodology. Technical capability and past performance are more important than price in the evaluation. The period of performance is from June 1, 2026, to May 31, 2027. Quotes are due by May 29, 2026, at 9:00 AM EDT, and must be submitted electronically to nicholas.capobianco@nih.gov. All offerors must be registered in SAM.gov.